Ligand-targeted liposomes directed against pathological vasculature

Raymond M Schiffelers; Grietje Molema; Timo L M ten Hagen; Adriënne P C A Janssen; Astrid J Schraa; Robbert J Kok; Gerben A Koning; Gert Storm

doi:10.1081/lpr-120004785

Ligand-targeted liposomes directed against pathological vasculature

J Liposome Res. 2002 Feb-May;12(1-2):129-35. doi: 10.1081/lpr-120004785.

Authors

Raymond M Schiffelers¹, Grietje Molema, Timo L M ten Hagen, Adriënne P C A Janssen, Astrid J Schraa, Robbert J Kok, Gerben A Koning, Gert Storm

Affiliation

¹ Dept of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, TB Utrecht, 3508, The Netherlands.

PMID: 12604046
DOI: 10.1081/lpr-120004785

Abstract

The development of liposomes targeted to angiogenic endothelial cells offers exciting prospects for intervention in cancer and inflammation. Several proteins are (strongly) over-expressed on angiogenic endothelial cells as compared to the quiescent endothelium, and could potentially serve as targets for site-specific drug delivery. In this contribution particular attention is given to the design of targeted long-circulating liposomes directed against the alpha v beta 3-integrin protein.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cells, Cultured
Doxorubicin / pharmacology
Endothelium, Vascular / cytology
Humans
Inflammation
Integrin alphaVbeta3 / metabolism
Integrins / metabolism
Ligands
Liposomes / metabolism*
Neovascularization, Pathologic / drug therapy*
Oligopeptides / pharmacology
Polyethylene Glycols / metabolism
Umbilical Veins / cytology

Substances

Integrin alphaVbeta3
Integrins
Ligands
Liposomes
Oligopeptides
Polyethylene Glycols
arginyl-glycyl-aspartic acid
Doxorubicin